<DOC>
	<DOCNO>NCT00970138</DOCNO>
	<brief_summary>Apatinib tyrosin-inhibitor agent target vascular endothelial growth factor receptor ( VEGFR ) , 's anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable maximum tolerable daily dose 850 mg . The purpose study determine whether apatinib improve progression free survival compare placebo patient metastatic gastric carcinoma fail two line chemotherapy .</brief_summary>
	<brief_title>Apatinib Versus Placebo Third Line Treatment Patients With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>Up , although FU base , cisplatin base taxane base regimen , ECF regimen suggest first line therapy A/MGC FDA , efficacy treatment still unsatisfied toxicity limitation prolong survival . Based promising result apatinib phase I study , clinical trial design evaluate whether apatinib improve progression free survival patient metastatic gastric carcinoma fail two line chemotherapy compare placebo . Patients randomize 3 group , one group patient receive treatment apatinib 850mg qd , one group patient receive apatinib 425mg bid , group receive placebo .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 70 year age Histologically confirm advanced metastatic adenocarcinoma stomach Have fail 2 line chemotherapy Life expectancy 3 month ECOG performance scale ≤ 2 At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Duration last therapy 6 week nitroso mitomycin More 4 week operation radiotherapy More 4 week cytotoxic agent growth inhibitor Adequate hepatic , renal , heart , hematologic function ( platelet &gt; 80 × 109/L , neutrophil &gt; 2.0 × 109/L , serum creatinine ≤ 1.5mg/dl , total bilirubin within upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ) . Pregnant lactating woman History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Any factor influence usage oral administration ; Evidence CNS metastasis History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix Intercurrence one following : hypertension , coronary artery disease , arrhythmia heart failure Receiving therapy thrombolysis anticoagulation Abuse alcohol drug Allergy ingredient agent two kind food drug Less 4 week last clinical trial Disability serious uncontrolled intercurrence infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Progress free survival</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Response rate</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Quality live</keyword>
</DOC>